Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Effects of acute high-intensity exercise on cognitive performance in trained individuals: A systematic review.

Browne SE, Flynn MJ, O'Neill BV, Howatson G, Bell PG, Haskell-Ramsay CF.

Prog Brain Res. 2017;234:161-187. doi: 10.1016/bs.pbr.2017.06.003. Epub 2017 Aug 1. Review.

PMID:
29031462
2.

Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Kalinichev M, Le Poul E, Boléa C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ, Raber J, Duvoisin R, Bate ST, Reynolds IJ, Poli S, Celanire S.

J Pharmacol Exp Ther. 2014 Sep;350(3):495-505. doi: 10.1124/jpet.114.214437. Epub 2014 Jun 19.

3.

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.

Smith KM, Browne SE, Jayaraman S, Bleickardt CJ, Hodge LM, Lis E, Yao L, Rittle SL, Innocent N, Mullins DE, Boykow G, Reynolds IJ, Hill D, Parker EM, Hodgson RA.

Eur J Pharmacol. 2014 Apr 5;728:31-8. doi: 10.1016/j.ejphar.2014.01.052. Epub 2014 Jan 31.

PMID:
24486705
4.

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.

Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ.

Front Neurosci. 2013 Dec 24;7:254. doi: 10.3389/fnins.2013.00254. eCollection 2013.

5.

When too much ATP is a bad thing: a pivotal role for P2X7 receptors in motor neuron degeneration.

Browne SE.

J Neurochem. 2013 Aug;126(3):301-4. doi: 10.1111/jnc.12321. Epub 2013 Jun 18. No abstract available.

6.

A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.

Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, Reynolds IJ.

J Pharmacol Exp Ther. 2012 Oct;343(1):167-77. doi: 10.1124/jpet.112.196063. Epub 2012 Jul 11.

PMID:
22787118
7.

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.

Huntington Study Group Pre2CARE Investigators, Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ.

Mov Disord. 2010 Sep 15;25(12):1924-8. doi: 10.1002/mds.22408.

PMID:
20669312
8.

PISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ.

Lubbers LS, Rowe BA, Hodge LM, Browne SE, Gundersdorf R, Jones P, Hess FJ, Reynolds IJ.

J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):319-28. doi: 10.1016/j.vascn.2010.01.012. Epub 2010 Feb 2.

PMID:
20132901
9.

Hypnosis in a GP obstetric unit.

Browne SE.

Pract Midwife. 2009 Apr;12(4):6. No abstract available.

PMID:
19444982
10.

Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models.

Browne SE.

Ann N Y Acad Sci. 2008 Dec;1147:358-82. doi: 10.1196/annals.1427.018. Review.

PMID:
19076457
11.

A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone).

Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K.

J Clin Pharmacol. 2007 Dec;47(12):1580-6. Epub 2007 Oct 9. No abstract available.

PMID:
17925590
12.

A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation.

Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong JS, Beal MF, Joh TH.

FASEB J. 2007 Jan;21(1):179-87. Epub 2006 Nov 20.

PMID:
17116747
13.

Oxidative damage in Huntington's disease pathogenesis.

Browne SE, Beal MF.

Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2061-73. Review.

PMID:
17034350
14.

Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.

Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF.

Neurobiol Dis. 2006 Dec;24(3):455-65. Epub 2006 Sep 29.

PMID:
17011205
15.

Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS.

Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, Beal MF.

Neurobiol Dis. 2006 Jun;22(3):599-610. Epub 2006 Apr 17.

PMID:
16616851
16.

Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Kim SY, Marekov L, Bubber P, Browne SE, Stavrovskaya I, Lee J, Steinert PM, Blass JP, Beal MF, Gibson GE, Cooper AJ.

Neurochem Res. 2005 Oct;30(10):1245-55.

PMID:
16341586
17.

Neurodegenerative disease.

Browne SE.

IDrugs. 1999 Jan;2(1):4-6.

PMID:
16180156
18.

Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.

Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF.

Neuromolecular Med. 2004;6(2-3):87-92.

PMID:
15970626
19.

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.

Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF.

J Biol Chem. 2005 Jan 7;280(1):556-63. Epub 2004 Oct 19.

20.

Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species.

Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF.

J Neurosci. 2004 Sep 8;24(36):7779-88.

21.

The energetics of Huntington's disease.

Browne SE, Beal MF.

Neurochem Res. 2004 Mar;29(3):531-46. Review.

PMID:
15038601
22.

Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice.

Browne SE, Roberts LJ 2nd, Dennery PA, Doctrow SR, Beal MF, Barlow C, Levine RL.

Free Radic Biol Med. 2004 Apr 1;36(7):938-42.

PMID:
15019978
23.

Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.

Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF.

J Neurochem. 2004 Mar;88(6):1352-60.

24.

CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.

Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M.

Hum Mol Genet. 2004 Apr 1;13(7):703-14. Epub 2004 Feb 12.

PMID:
14962978
25.

Minocycline enhances MPTP toxicity to dopaminergic neurons.

Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS.

J Neurosci Res. 2003 Oct 15;74(2):278-85.

PMID:
14515357
26.

Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis.

Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, Beal MF.

J Neurochem. 2003 Apr;85(1):142-50.

27.

Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression.

Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK.

Neurobiol Dis. 2002 Dec;11(3):410-24.

PMID:
12586550
28.

Toxin-induced mitochondrial dysfunction.

Browne SE, Beal MF.

Int Rev Neurobiol. 2002;53:243-79. Review. No abstract available.

PMID:
12512343
29.

High risk pregnancy in the workplace. Influencing positive outcomes.

Cannon RB, Schmidt JV, Cambardella B, Browne SE.

AAOHN J. 2000 Sep;48(9):435-46; quiz 447-8. Review.

PMID:
11760291
30.

N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.

Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ.

J Neurochem. 2001 Dec;79(5):1109-12.

31.

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.

Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF.

Neurobiol Dis. 2001 Jun;8(3):479-91.

PMID:
11447996
32.
33.

Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment.

Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JP, Gibson GE, Beal MF.

J Neurochem. 2000 Feb;74(2):878-81.

34.

Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation.

Simon DK, Pulst SM, Sutton JP, Browne SE, Beal MF, Johns DR.

Neurology. 1999 Nov 10;53(8):1787-93.

PMID:
10563629
35.

Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex.

Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF.

Neurosci Lett. 1999 Sep 3;272(1):53-6.

PMID:
10507541
36.

The cerebral metabolic consequences of nitric oxide synthase deficiency: glucose utilization in endothelial and neuronal nitric oxide synthase null mice.

Browne SE, Ayata C, Huang PL, Moskowitz MA, Beal MF.

J Cereb Blood Flow Metab. 1999 Feb;19(2):144-8.

PMID:
10027769
37.

Oxidative stress in Huntington's disease.

Browne SE, Ferrante RJ, Beal MF.

Brain Pathol. 1999 Jan;9(1):147-63. Review.

PMID:
9989457
38.

The cerebral metabolic effects of manipulating glutamatergic systems within the basal forebrain in conscious rats.

Browne SE, Muir JL, Robbins TW, Page KJ, Everitt BJ, McCulloch J.

Eur J Neurosci. 1998 Feb;10(2):649-63.

PMID:
9749726
39.

Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis.

Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH Jr, Beal MF.

J Neurochem. 1998 Jul;71(1):281-7.

40.

Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis.

Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, Beal MF.

J Neurochem. 1997 Nov;69(5):2064-74.

41.

Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis.

Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr.

Ann Neurol. 1997 Oct;42(4):644-54.

PMID:
9382477
42.

Iodoacetate produces striatal excitotoxic lesions.

Matthews RT, Ferrante RJ, Jenkins BG, Browne SE, Goetz K, Berger S, Chen IY, Beal MF.

J Neurochem. 1997 Jul;69(1):285-9.

43.

Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.

Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF.

Ann Neurol. 1997 May;41(5):646-53.

PMID:
9153527
44.

Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.

Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF.

J Neurochem. 1995 Feb;64(2):936-9.

PMID:
7530297
45.
46.
47.

Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases.

Browne SE, Beal MF.

Biochem Soc Trans. 1994 Nov;22(4):1002-6. Review. No abstract available.

PMID:
7698395
48.

AMPA receptor antagonists and local cerebral glucose utilization in the rat.

Browne SE, McCulloch J.

Brain Res. 1994 Mar 28;641(1):10-20.

PMID:
8019834
49.

Pharmacological modification of glutamate neurotoxicity in vivo.

Fujisawa H, Dawson D, Browne SE, MacKay KB, Bullock R, McCulloch J.

Brain Res. 1993 Nov 26;629(1):73-8.

PMID:
7506985
50.

An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol.

Pertwee RG, Browne SE, Ross TM, Stretton CD.

Pharmacol Biochem Behav. 1991 Nov;40(3):581-5.

PMID:
1666920

Supplemental Content

Loading ...
Support Center